First Japanese Patient Treated with Parathyroid Hormone Peptide Immunization for Refractory Hypercalcemia Caused by Metastatic Parathyroid Carcinoma

ICHIRO HORIE¹), TAKAO ANDO¹), NAOKO INOKUCHI²), YUMI MIHARA³), SHIRO MIURA³), MISA IMAIZUMI¹), TOSHIRO USA¹), NAOE KINOSHITA⁴), ICHIRO SEKINE⁵), SHIMERU KAMIHARA³) AND KATSUMI EGUCHI¹)

¹)First Department of Medicine, Nagasaki University School of Medicine, Nagasaki 852-8501, Japan
²)Department of Laboratory Medicine, Nagasaki University School of Medicine, Nagasaki 852-8501, Japan
³)Division of Tumor and Diagnostic Pathology, Nagasaki University School of Medicine, Nagasaki 852-8501, Japan
⁴)Department of Pathology, Nagasaki University School of Medicine, Nagasaki 852-8501, Japan

Abstract. Patients with unresectable parathyroid carcinoma develop severe hypercalcemia, bone fractures and renal failure, and become unresponsive to conventional treatments. It has been shown that successful induction of anti-parathyroid hormone (PTH) antibodies, using PTH peptide fragments for immunisation, normalized serum levels of calcium as well as improved clinical symptoms. Here, we report our experience of PTH immunization in a Japanese female suffering from refractory hypercalcemia and renal failure caused by unresectable metastatic parathyroid carcinoma. Upon immunization, there were apparent clinical responses including reduction of serum levels of Ca along with anti-PTH antibodies induction. Therefore, we concluded that PTH immunization was an effective treatment against hypercalcemia caused by metastatic parathyroid carcinomas that are unresponsive to conventional treatments.

Key words: PTH, Parathyroid, Carcinoma, Metastasis, Immunization

PARATHYROID CARCINOMA is rare cause (less than 1%) of primary hyperparathyroidism [1]. Typically, higher serum levels of parathyroid hormone (PTH) are seen in parathyroid carcinoma (3 to 10 times, or even higher, the upper limit of the reference range) than in parathyroid adenoma and hyperplasia and are associated with extreme hypercalcemia (>14mg/dL) [1, 2]. There may be associated severe bone pain and osteitis fibrosa cystica [1]. Parathyroid carcinoma is an indolent tumor with low malignant potential and, in general, has a tendency to recur locally in the operative site or spread into contiguous tissues in the neck. Distant metastases are a late phenomenon with lymphatic or hematogenous spread to cervical lymph nodes and lungs and less commonly to the liver. The optimal treatment for parathyroid carcinoma is complete resection of the primary site, en bloc, including the surrounding tissues.

When metastatic parathyroid tumors are found, surgical resection of the metastatic tumors is the optimal treatment. This is because parathyroid carcinoma is refractory to radiation and cytotoxic reagents [1]. Medical management of hypercalcemia by infusing large amounts of fluid, along with bisphosphonates and perhaps calcitonin is briefly effective but, hypercalcemia eventually becomes uncontrolable. Recently, cinacalcet, a calcimimetic agent [3], has been used effectively to reduce hypercalcemia in patients with primary hyperparathyroidism [4] and ~ two thirds of patients with parathyroid carcinoma also respond [5]. However, this treatment was not available in Japan for our patient in 2007, and, moreover, long-term efficacy has not been well established and calcimimetics do not inhibit proliferation of parathyroid cancer cells.

It was recently shown that immunization with PTH peptides was effective in controlling hypercalcemia...
for more than 72 months in a patient with unresectable parathyroid carcinoma [6, 7] and caused resolution of metastatic tumor deposits [7]. This treatment is dependent on a strong host immune response against a limited set of PTH peptides immunogens and all patients were Caucasian [6-8]. Here we attempted PTH immunization in a Japanese patient suffering from uncontrolled hypercalcemia caused by unresectable parathyroid carcinoma.

**Patient**

A 34 year-old Japanese female was referred to our hospital because of markedly elevated serum levels of Ca (19.4 mg/dL; reference range: 9.0-10.6 mg/dL) in October 2006. Serum levels of intact PTH were elevated at 1148 pg/mL; (reference range: 10.3-65.9 pg/mL; Eclusis PTH, Roche Diagnostic K.K., Tokyo, Japan) while serum levels of PTH-related peptide and angiotensin-converting enzyme were normal. Neck ultrasound and CT clearly identified two hypoechoic and low density nodules behind the right lobe of the thyroid which were also abnormal by $^{99m}$Tc-methoxyisobutyl-isonitrile scintigraphy. Subsequently, the enlarged parathyroid glands were removed with the surrounding thyroid, en bloc, and a pathological diagnosis of parathyroid carcinoma was made with tumor invasion of the thyroid gland and veins. Postoperatively, serum levels of Ca normalized to below 10.0 mg/dL. However, intact PTH remained higher than 200 pg/mL, indicating residual parathyroid tissue. However, we were not able to identify such lesions.

Over the following two months, there was a progressive increase in serum levels of Ca (Fig 1A) and intact PTH. At subsequent readmission the patient underwent a FDG-PET scan of the upper neck that identified a bone destructive tumor in the dental process (dens) in the C2 vertebra which was confirmed by CT and MRI. Since this was not surgically accessible, it was targeted with 50 Gray of intensity modulated radiation therapy (IMRT) with a peripheral margin of 2mm receiving 45 Gray.

However, beneficial effects over the following month were not apparent. Serum levels of Ca were

---

**Fig. 1.** Clinical course of the patient with parathyroid carcinoma treated with PTH immunization.

Serum levels of Ca (A), Cr (B), and intact PTH with (white dots) or without (black dots) PEG precipitation (C). Days after the first admission are indicated in the X axis. Note that the progressive increase in serum levels of Ca was stabilized after PTH immunization was initiated as indicated by black inverted triangles in the top of the panel (A), and also that dramatic reduction of PTH after PEG precipitation is apparent only after PTH immunization (C).
maintained at less than 15mg/dL with a large amount of a fluid infusion combined with weekly zoledronate. After obtaining written informed consent from the patient and her family, and approval from the Nagasaki University Hospital ethic committee, we commenced PTH peptide immunotherapy.

**PTH peptides**

Immunogenic preparations of PTH peptides were generated as described previously [6, 7]. Briefly, peptide sequences of human PTH1-34 (bioactive amino-terminal sequence), PTH33-52, and PTH 51-84 were synthesized. Single amino-acid modifications were made at position two of each peptide, and separately at position three for PTH1-34, in an attempt to improve antigenicity. Antigenicity was further increased by constructing octomeric, multi-antigenic peptides connected to a lysine core (Alta Biosciences, University of Birmingham, Birmingham, UK). Immunogens were dialyzed against sterile saline and combined in a proportion of 40:60 with complete Freund’s adjuvant.

**Immunization procedure and detection of anti-PTH antibodies**

In each immunization, PTH peptides were given intradermally targeting the cervical, axillary, anterior thoracic, and inguinal lymph nodes. In the subsequent immunization, the alternative side of the body was used for immunization every 4-5 weeks. In the first three immunizations, only human PTH1-34 peptides were used. From the third immunization, we included not only PTH1-34 peptides but also PTH33-52 and PTH51-84 peptides as immunogens. Sera were collected before and two weeks after each immunization and anti-PTH antibodies were studied as previously described [6, 7].

**Study of free and antibody-bound PTH by polyethylene glycol precipitation**

Polyethylene glycol precipitation (PEG) of sera was performed as previously described [9]. Briefly, sera were mixed with an equal volume of 25% PEG6000 and the supernatants obtained by centrifuging were assessed for serum levels of intact PTH.

**Histological detection of PTH and Ki67**

Deparaffinized tissue sections obtained at surgical operation and autopsy were stained with anti-PTH mouse monoclonal antibodies (1:200) (Novocastra, Newcastle, UK) or Ki 67 antibodies (1:100) (Dako, Japan) using routine methods [10].

**Results**

After the first immunization, using N terminus of the PTH (PTH1-34), there was a pyrexia of over 39°C for 3 days, then skin ulcerations developed at all seven immunization sites. Anti-PTH antibodies were weakly detectable in sera taken two weeks after the first and second (A), third (B), and fourth and fifth immunization (C) were studied. Sera collected prior to the immunization (pre) and the unrelated peptide were also included as negative antibody control and as negative antigen control, respectively.

After the second immunization with PTH 1-34, serum levels of intact PTH increased from 2,036 to 3,627 pg/mL while serum levels of Ca decrease to 14 mg/dL. This suggested the presence of immunoglobulin/PTH immune complexes, a supposition that was supported by rising titres of antibodies to PTH1-34 (Fig 2B) observed using dot-blot analysis. It was decided to stop hemodialysis. Having inducing a good immune response to PTH1-34, N terminus as well as middle (PTH33-53) and C terminus (PTH52-84) immunogens were used from the third to fifth immunization. The reason of not including middle or C terminus peptides in the first and second immunization was due to a concern of a potential activation of PTH receptor by IgG-bound PTH, which
seems to have longer half-life than PTH itself, without inducing antibodies to PTH N terminus. Serum levels of intact PTH rose further to ~6,000, ~7,500, and finally ~12,000 pg/mL after the third, fourth, and fifth immunization, respectively. Dot-blot analysis showed progressive increases in antibody titers to all the PTH fragments (Fig 2B and C). Correspondingly, serum Ca decreased below 14 mg/dL within a week after each immunization. Unfortunately, such beneficial effects were transient and serum levels of Ca gradually increased to over 15 mg/dL within 3 weeks of the injections. Therefore, immunization was repeated every four weeks.

Such transient therapeutic effects of the PTH immunization were not as evident in previously successfully treated patients [6-8]. Since the antibody titres were high, yet ineffective, we considered that parathyroid carcinoma was either growing rapidly or had highly efficient PTH production. Subsequent whole body CT scans detected multiple metastases in the lungs and liver. There was an additional osteolytic lesion in the neck of the left femur (not shown), that was also considered to be metastatic tissue. These lesions had not been identified before the PTH immunization indicating a highly aggressive tumor. This offered an explanation for the poor clinical result despite effective immunization.

From the clinical picture it was obvious that the patient was terminally ill, after extensive discussions with family members about the advantages and disadvantages of continuing immunization in the current clinical status, 6th immunization was performed. However, a high-output heart failure developed leading to hypotensive shock and death.

At postmortem, we identified a small (7 mm) subpleural nodule in the right lung and multiple masses in the liver (5-20 mm in the diameter) and a metastasis in the dens of the second vertebra. Microscopic studies showed cell proliferation with palisading, rosette-formation and honeycomb structures characteristic of endocrine tumors (Fig 3A), and cells stained positively with anti-PTH antibody (Fig 3B). Proliferating cells, as studied by Ki-67 labeling indices, were 2.1 % in the primary tumor (Fig 3C), 0.4 % in the metastatic lung tumor (Fig 3D) and 0.8 % in the metastatic liver tumor (not shown). There was no apparent tumor necrosis or fibrosis in the metastatic lesion in the second cervical vertebra (not shown) where IMRT had been targeted. Her heart displayed severe concentric hypertrophy. There was severe pulmonary edema accounting for death by heart failure.

Having shown that PTH immunization was successful in this patient, we wondered how serum levels of Ca fell down in the presence of elevating serum levels of intact PTH. Since the immunization induced anti-PTH antibodies, we decided to measure free and antibody-unbound PTH in the sera. By utilizing Peg precipitation, it was clear that the free PTH levels were much less after immunizations (Fig 1C).

**Discussion**

PTH immunization was originally attempted in a patient with uncontrolled hypercalcemia caused by metastatic parathyroid carcinoma[6]. Subsequently, several patients with unresectable parathyroid carcinoma have been treated [6-8]. Most of the enrolled patients showed positive immune response to PTH peptides, as determined by dot blots, showing favorable clinical responses including reduced concentrations of serum Ca. Clinical responses in responders normally occurred after the first or second immunization. In addition to lowering serum levels of Ca, tumor shrinkage was seen in a patient upon immunization [7]. Adverse
IMRT is to irradiate the target by using several radiation beams of varying intensity and is expected to improve dose homogeneity while sparing the surrounding important tissue nearby the target because of its way of irradiation [18]. However, as described, IMRT was not effective to metastatic parathyroid carcinoma in our patient.

In summary, we report our experience of PTH immunization performed on a Japanese patient with metastatic parathyroid carcinoma. Since our case was highly aggressive, there was minimal remission of hypercalcemia. However, PTH immunization effectively provoked a host immune response against PTH peptides and partly neutralized PTH produced from the tumor. Therefore, PTH immunization should be considered for patients with severe hypercalcemia caused by metastatic parathyroid carcinomas that are unresponsive to conventional treatments.

Acknowledgements

We thank Dr Arthur R. Bradwell, the Division of Immunity and Infection, Medical School University of Birmingham, Birmingham, United Kingdom, for his generosity to provide us PTH peptides and to examine serum anti-PTH antibodies by dot blots, as well as his critical suggestions to the manuscript.

References


